How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million not $300 million? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. With the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

We expect CRISPR Therapeutics CRSP to surpass expectations when it reports second-quarter 2024 results next month. Let’s see how things have shaped up for the quarter to be reported. CRISPR ...

“It’s a little scary, quite honestly,” says Dr. Jennifer Doudna, who helped develop CRISPR gene-editing technology. By David Marchese It’s entirely possible, maybe even likely, that during some slow ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

Five years ago this month, in November 2020, medical history was made at London-based contract research organisation, Richmond Pharmacology, when a patient received the first CRISPR therapy delivered ...